Significantly more women reported moderate or high sexual desire following bremelanotide vs placebo (p = 0.0114), and among women attempting intercourse within 24 hours of treatment, significantly more reported satisfaction with their level of sexual arousal following bremelanotide vs placebo (p = 0.0256) providing the foundational female sexual dysfunction dataset that directed PT-141 toward HSDD clinical development
Preferred injection sites are the abdomen (away from the navel), upper thighs, and upper arms
CoxALThompsonSAJonesJLRobertsonVHHaleGWaldmannHet al
Both tests came back negative: AOD9604 did not cause mutations in bacteria and did not damage chromosomes in mammalian cells
Importantly, we covered multiple viewpoints: physicians whose clinics now use ePA, pharmacists who no longer juggle as many phone calls, and payers pledging to simplify processes under new accords ( [13] ) ( [63] )
Theres no solid evidence so far